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Recent technical improvements in evaluations of immune cells in situ and immune moni-
toring of patients with cancer have provided a wealth of new data confirming that immune
cells play a key role in human cancer progression. This, in turn, has revived the expecta-
tion that immune endpoints might serve as reliable biomarkers of outcome or response to
therapy in cancer. The recent successes in linking the T-cell signature in human colorectal
carcinoma (CRC) with prognosis have provided a strong motive for searching for additional
immune biomarkers that could serve as intermediate endpoints of response to therapy
and outcome in human cancers. A number of potentially promising immune biomarkers
have emerged, but most remain to be validated. Among them, the B-cell signature, as
exemplified by expression of the immunoglobulin G kappa chain (IGKC) in tumor-infiltrating
lymphocytes (TIL), has been validated as a biomarker of response to adjuvant therapy and
better survival in patients with breast carcinoma and several other types of human solid
tumors. Additional immune endpoints are being currently tested as potentially promising
biomarkers in cancer. In view of currently growing use of immune cancer therapies, the
search for immune biomarkers of prognosis are critically important for identifying patients
who would benefit the most from adjuvant immunotherapy.
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INTRODUCTION
It has been well established that the development of cancer is asso-
ciated with alterations in numbers and functions of immune cells
in the peripheral circulation and especially at the sites of tumor
progression. More recently, a possibility has emerged that immune
measures could serve as biomarkers or as surrogate endpoints of
clinical responses. However, despite considerable progress made
in immune monitoring methods, it has been difficult to correlate
changes in the host immune profile associated with cancer pro-
gression or cancer therapy to clinical endpoints. This difficulty
in establishing meaningful correlations of immune with clini-
cal endpoints has been variously attributed to the complexity of
interactions between the host immune system and the tumor, an
inadequate quality of immune monitoring used to measure these
interactions and/or a failure to measure those aspects of immune
responses that are most relevant to cancer progression. Recent
progress in our understanding of cellular and molecular pathways
involved in immune responses to cancer has greatly facilitated the
selection of the most relevant immune endpoints to evaluate. Also,
impressive technological advances in methods allowing for multi-
plex profiling of immune phenotypes, definition of regulatory cell
subsets, identification of critical signaling molecules, and recogni-
tion of biologically important targets, all have increased our ability
to begin to discover potential immune biomarkers of disease-free
or overall survival.
The need for robust biomarkers of outcome in cancer is
especially great today. In the era of personalized medicine and
the rapidly expanding availability as well as the use of bio-
therapies in cancer, a requirement for immunologic biomarkers
of therapeutic efficacy is especially strong. To help fulfill this
requirement, the recently published recommendations of the joint
SITC/NCI/FDA Taskforce for the development and use of bio-
markers in immunotherapy trials offer guidelines for how to
establish, standardize, and evaluate immune assays, so that they
meet a biomarker designation (Butterfield et al., 2011a).
The question of whether and how the host immune system
influences cancer development has been debated for decades.
While studies in animal models of cancer strongly support the role
of anti-tumor immunity in cancer development, progression, and
therapy, evidence from human clinical trials is not clear or straight-
forward. This may be in large part due to profoundly immunoin-
hibitory effects human tumors exert (Huang et al.,2008;Whiteside,
2008b), with the result that cancer patients at best mount weak
anti-tumor immune responses which are ineffective in controlling
cancer progression (Whiteside et al., 2011). Given that tumor-
induced immune suppression exists, promotes tumor escape, and
thus creates a major problem for cancer therapy (Whiteside et al.,
2011), it might be possible to use immunosuppression as a measure
of patients’ immune competence or more precisely, of a deficiency
in immune competence specifically targeted to the tumor. Thus,
one could measure: (a) the degree of tumor-induced immune sup-
pression by identifying a decrease in or absence of an anti-tumor
immune response or (b) the degree of recovery from immune sup-
pression after successful therapy (i.e., normalization of defective
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anti-tumor immune responses). In the first instance, the immune
evaluation takes place at the time of diagnosis and prior to any
therapy; in the second, it takes place prior to, during and after ther-
apy. Both these approaches have been used in clinical trials with
the hope that intermediate biomarkers of immune suppression
as well as biomarkers of therapy-induced recovery can be iden-
tified. Because of the complexity of host-tumor interactions and
limited immune monitoring capabilities, both have been difficult
to implement in practice. Nevertheless, current evidence suggests
that in a sufficiently large cohort of cancer patients with similar
demographic and clinicopathologic features, the disease-related
or therapy-related immunological alterations can be detected and
reliably measured. Further, in a limited number of cases, such
immune alterations have been shown to correlate with clinical out-
come suggesting that upon validation, they might serve as future
biomarkers of prognosis or response to therapy.
While promising, these results are preliminary, and in most
cases, validation of these potential immune biomarkers remains
to be performed. Nevertheless, there is an expectation that in the
near future, some of these immune biomarkers will be serving
as reliable intermediate endpoints facilitating the management of
patients with cancer and providing insight into the selection of
most effective therapeutic strategies for these patients. The pur-
pose of this communication is to describe a handful of most
promising immunological assays that are currently being evalu-
ated as intermediate biomarkers of cancer progression, regression,
or recurrence.
“IMMUNE SCORE” IN THE TUMOR MICROENVIRONMENT
Human solid tumors are nearly always infiltrated by immune cells
(Whiteside, 1993). While the composition and extent of these
inflammatory infiltrates vary among tumors, they represent solid
evidence that the host immune system is engaged in surveying
tumor development. The tumor microenvironment is known to
have a strong impact on immune cells, and the identity, phenotype,
localization, and density of immune cells present in the tumor has
long been considered by immunologists to be critically impor-
tant for tumor progression (von Kleist et al., 1987). Immune cells
infiltrating human solid tumors have been extensively studied and
found to exhibit unique phenotypic and functional characteristics
(Pages et al., 2010; Fridman et al., 2012). While the presence and
functions of T cells in the tumor were the major concern in many
earlier studies, more recent data emphasize the diversity in cellular
composition of immune tumor infiltrates in various tumor types,
with B cells, NK cells, M1 and M2 macrophages, granulocytes, or
mast cells contributing substantially to the “immune signature”
that uniquely characterizes each solid tumor.
THE T-CELL SIGNATURE
Typing of tumor-infiltrating T lymphocyte (TIL) cells by immuno-
histochemistry (IHC) and microscopic enumeration of these
cells have been initially utilized to establish correlations between
CD3+CD8+T-cell infiltrations and prognosis (Naito et al., 1998).
These studies have indicated a potential significance of CD8+ T
cells as predictors of risk (Sato et al., 2005). However, human TIL
were found to be functionally impaired relative to peripheral blood
T cells of patients or of normal donors (Frey and Monu, 2008;
Whiteside, 2010) and, in some instances, TIL were shown to con-
tribute to tumor progression (Whiteside, 2006). Most of these early
in situ studies of TIL were small, retrospective, and probably biased
due to the use of imperfect manual cell counts. Nevertheless, they
have initiated an intense debate as to whether TIL were harbingers
of good or poor prognosis. As Rosenberg’s group at the NCI and
other investigators were successful in expanding TIL for adoptive
therapy, it appeared that if these cells were functionally deficient
in situ, they clearly re-gained the ability to eliminate tumor cells
upon culture in the presence of IL-2 (Dudley et al., 2003). Slowly,
the realization that the host-tumor interactions are critical for
determining the fate of immune cells found in the tumor microen-
vironment prompted the re-assessment of the role TIL play in
cancer progression. It was the report on TIL in colorectal cancer
(CRC) published by Galon et al. (2006) in Science in 2006 that
convincingly altered our perception of the prognostic significance
of these T cells in cancer. Using modern techniques of systems
biology and an objective scoring system based on image analy-
sis, Galon et al.’s (2006) data showed that the type, density and
location of immune cells within tumors predicted positive clin-
ical outcome. Subsequently, Fridman’s group has demonstrated
by immunostaining of hundreds of CRC specimens that a strong
local immune reaction, including CD3+, CD8+, and memory
CD45RO+ T cells, correlates with a favorable prognosis regard-
less of the local extent of the tumor or the regional lymph node
involvement (Pages et al., 2005; Fridman et al., 2011). At the same
time, independent reports from various other laboratories on the
nature and cellular composition of immune infiltrates into human
solid confirmed prognostic significance of the T-cell signature in
cancer (Pages et al., 2005; Fridman et al., 2011). T-cell infiltrates
emerged as the stronger independent prognostic factor than the
conventional clinicopathological criteria such as tumor size, depth
of infiltration, differentiation, or the nodal status (Galon et al.,
2012). Based on these results, a proposal has been crafted for a
routine evaluation of the tumor microenvironment for the den-
sity, location, phenotype, and function of T cells in order to define
“an immune score” for each tumor as a part of the standard patho-
logic examination (Galon et al., 2012). While the proposal for the
use of the immune score in pathology is supported by impres-
sive globally collected data, it remains unclear whether and how
soon this practice will be embraced by the pathologists. Of con-
cern are issues related to the standardization of methods for a
routine clinical use and requirements for automated image analy-
ses. Nevertheless, at present, the immune score emerges as the
first immunologic marker of risk in cancer with a potential to be
incorporated into prognostically relevant immune classification
of human CRC equal to or better than the conventional TNM
classification (Galon et al., 2012).
THE FREQUENCY OF TUMOR-SPECIFIC T CELLS IN THE
CIRCULATION
In addition to scoring T cells at tumor sites, the frequency and
functions of T cells circulating in the peripheral blood of can-
cer patients have been examined as potential biomarkers. The
availability of standardized single-cell assays able to detect tumor-
antigen-specific T cells (ELISPOT, cytokine flow cytometry (CFC),
and tetramer binding) has facilitated evaluation of epitope-specific
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T cells as potential biomarkers (Britten et al., 2011). These assays,
especially ELISPOT, have been standardized for serial monitor-
ing (Britten et al., 2011) and can be reliably utilized to measure
the frequency of epitope-specific T cells in blood or body fluids.
While both CFC and tetramer assays require flow cytometry and
thus are restricted to facilities equipped with a cytometer oper-
ated by a skilled technologist, ELISPOT is not. Perhaps for this
reason, ELISPOT has become the most widely used single-cell
monitoring assay. Also, while CFC and tetramer assays only mea-
sure the frequency of cells expressing a particular marker,ELISPOT
defines the frequency of T cells able to respond to the recognized
epitope by cytokine (e.g., IFN-γ) production. Thus, ELISPOT
detects functional T cells (Whiteside, 2008a). In a recent ECOG-
sponsored 1696 Phase II multi-center trial testing vaccination with
melanoma peptides delivered alone, with GM-CSF, IFN-α2b, or
both cytokines to HLA-A2+ patients with metastatic melanoma,
we serially monitored the frequency of CD8+tetramer+ (tet+)
T cells, their differentiation stages, and ELISPOT responses of
CD8+ T cells to the vaccinating peptides (Schaefer et al., 2012).
When these immunologic results were related to patients’ clini-
cal responses, only IFN-γ ELISPOT results correlated with clinical
responses, and neither the frequency of CD8+tet+ T cells in the
periphery nor their differentiation stage were significant correlates
of outcome (Schaefer et al., 2012). The data suggested that only the
functional status of tumor peptide-specific CD8+ T cells, and not
their phenotype or differentiation, served as a relevant biomarker
for correlating immune and clinical responses to a peptide-based
anti-tumor vaccine (Schaefer et al., 2012).
It has been suggested that the breadth of an immune response
to tumor-associated peptides rather any one expanded response
to a single peptide might correlate better with clinical response
to immune therapy, especially to anti-tumor vaccines (Butterfield
et al., 2003). In aggregate, data from multiple clinical studies sug-
gest that patients who are able to mount immune responses to
multiple as opposed to a single tumor-associated peptide have
better prognosis. In the melanoma vaccine study discussed above,
the breadth of immune responses (defined as an “immune score”)
was greater for patients who remained disease-free than those with
progressive disease (Schaefer et al., 2012).
APOPTOSIS OF CD8+ T CELLS
Tumor-derived factors have been shown to induce death of
immune cells at the tumor sites and in the peripheral circulation
(Whiteside, 2010). The frequency of CD8+ T cells undergoing
spontaneous apoptosis in the blood of patients with cancer was
found to be significantly elevated relative to that in sex- or age-
matched healthy controls (Hoffmann et al., 2002). CD8+ T cells
were preferentially targeted for cell death compared to circulating
CD4+ T cells (Tsukishiro et al., 2003). Further, evidence suggests
that in cancer, tumor epitope-specific T cells are preferentially
eliminated either directly via the Fas/FasL or Trail/TRAILR path-
ways (Albers et al., 2006) or indirectly through the release of
tumor-derived exosomes (TEX) carrying death receptor ligands
(Kim et al., 2005b). The propensity of T cells to undergo spon-
taneous apoptosis was measured by Annexin V binding and flow
cytometry in several cohorts of patients with head and neck squa-
mous cell carcinoma (HNSCC), and in these pre-clinical studies,
the frequency of Annexin V-binding CD8+T cells was shown to
discriminate patients with cancer from normal controls (Tsuk-
ishiro et al., 2003). However, using Annexin V binding, it was
not possible to discriminate HNSCC patients with active dis-
ease from those with no evident disease following conventional
therapies (Tsukishiro et al., 2003). The sensitivity of T CD8+ T
cells to apoptosis was linked to high levels of Fas expression in
the majority of these cells present in the peripheral circulation,
and both the frequency of Fas+CD8+ T cells and expression lev-
els of Fas on these cells were significantly increased in patients
with advanced disease, a large tumor burden, and those with the
metastatic lymph node involvement (Hoffmann et al., 2002; Tsuk-
ishiro et al., 2003). In more recent studies, Annexin V binding
to CD8+ T cells in patients with HNSCC was found to be a less
sensitive endpoint in discriminating patients from controls than
the frequency of circulating CD8+ CCR7+ T cells, as discussed
below (Czystowska et al., 2012). FasL+microvesicles isolated from
plasma of cancer patients have been linked to tumor progression,
demonstrating that the presence of membrane-tethered FasL, and
potentially of other molecules such as PDL-1 or TGF-β, could
contribute to apoptosis of anti-tumor effector cells and thus to
tumor escape (Whiteside, 2013). These studies suggest that the
presence of death-inducing ligands or other immunosuppressive
cargo in TEX might have prognostic value in patients with cancer
(Whiteside, 2013).
THE DIFFERENTIATION STATUS OF CD8+ T CELLS
Although the functional potential of tumor epitope-specific T cells
in situ or in the peripheral circulation of patients with cancer has
been shown in some studies to correlate with outcome (Kirkwood
et al., 2009), performing of functional immune assays is demand-
ing and costly. A search for alternative biomarkers suggested that
T-cell differentiation, as measured by expression on CD8+ T cells
of CCR7, a chemokine receptor for CCL19 and CCL21, discrim-
inated cancer patients from normal controls (Czystowska et al.,
2012).
We observed that in patients with HNSCC tested at the time of
diagnosis, the frequency of CD8+CCR7+ T cells in the periph-
eral blood assessed by flow cytometry was significantly and often
dramatically decreased relative to that in age- and sex-matched
NC (Kim et al., 2005a). Using recursive partitioning statistics, we
showed that the frequency of 28% CD8+CCR7+ T cells in the
blood discriminated cancer patients from NC with a high degree of
accuracy (Czystowska et al., 2012). We, therefore, inquired whether
the paucity of CD8+CCR7+ T cells in the circulation at diagnosis
and prior to any curative therapy could serve as a risk factor for
the disease recurrence. Peripheral blood in a small cohort (n= 25)
of previously untreated HNSCC patients with active disease was
studied for the frequency of CD8+CCR7+T cells at diagnosis. The
patients were treated with conventional therapies and followed for
up to 4 years for cancer recurrence. Remarkably, disease-free sur-
vival (DFS) was found to be significantly shorter for patients with
fewer than 28% of circulating CD8+CCR7+ T cells at diagnosis
compared to patients with>28% of these T cells (Czystowska et al.,
2012). These results suggest that the frequency of CD8+CCR7+
T cells at diagnosis might play a role in cancer control regardless
of definitive therapy these patients subsequently receive. Thus, a
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simple blood test at diagnosis could have a prognostic value in
determining a possibility of the disease recurrence in HNSCC.
These data are encouraging but preliminary, and the predictive
value of this flow cytometry-based assay needs to be confirmed in
additional much larger prospective studies. Nevertheless, the data
provide preliminary evidence that immune biomarkers based on
T-cell differentiation could be useful in predicting recurrence in
HNSCC.
THE B-CELL SIGNATURE
To date, a search for promising immune correlates of cancer diag-
nosis, prognosis, and survival has been largely limited to T-cell
responses. In their definition of the immune score, Fridman and
colleagues rarely mention B cells or plasma cells. Yet, considerable
evidence has existed for the presence of these cells in tumors, espe-
cially in breast cancer (Coronella et al., 2002). More recently, two
independent reports have provided useful insights into the prog-
nostic role of B cells in cancer. Schmidt et al. (2008, 2012) have
reported convincing data that validate the B-cell signature as the
most robust prognostic factor in breast cancer and other human
tumors. These investigators identified the immunoglobulin G
kappa chain (IGKC) as an immunologic biomarker of prognosis
and response to chemotherapy in hundreds of patients with breast
cancer, non-small lung cancer, and CRC (Schmidt et al., 2012). In
this multi-institutional study, the IGKC was microscopically iden-
tified as a product of plasma cells present in the tumor stroma and
was validated as a prognostic biomarker by the RNA- and protein-
based expression studies independently performed in thousands
of formalin-fixed, paraffin-embedded specimens at 20 different
centers (Schmidt et al., 2012). Expression of the IGKC transcript
was the strongest discriminator of patients with breast cancer with
and without metastases among the 60 genes found in the B-cell
metagene, while transcripts of the T-cell metagene had lesser prog-
nostic significance (Schmidt et al., 2008). Infiltrates of both T and
B cells were found to be associated with better prognosis (Schmidt
et al., 2008). However, the most important finding was that IGKC
predicted responses to neoadjuvant therapy in breast cancer and
thus qualifies it as the first immune marker of response to cancer
treatment. In view of an ongoing debate among tumor immunol-
ogists about the role of humoral vs. cellular immunity in tumor
development, progression, and therapy, the above finding of the B-
cell signature as a validated biomarker of prognosis and response
to therapy provides a strong support for the role of humoral
immunity in controlling cancer (Whiteside and Ferrone, 2012).
In support of this key role of the B-cell signature, Nielsen et al.
(2012) recently reported that among TIL present in high-grade
serous ovarian carcinomas, CD20+ B cells co-localized with acti-
vated CD8+T cells and expressed markers of antigen presentation,
including MHC class I, MHC class II, CD40, CD80, and CD86.
These B cells were antigen experienced. The presence among TIL
of both CD20+ B and CD8+ T cells correlated with increased
patient survival compared with CD8+ T cells alone. Although
these CD20+ B cells had an atypical CD27(−) memory B-cell
phenotype, together with CD8+ T cells, they promoted favorable
prognosis in ovarian cancer (Nielsen et al., 2012).
In an earlier study, Pretscher et al. (2009) have reported that in
head and neck cancer (HNC), intra-tumoral CD20+ B cells were
significantly more frequent in metastatic lesions than in primary
tumors. Further, large numbers of peritumoral B cells together
with increased numbers of intraepithelial CD8+T cells in metasta-
tic tumors were associated with favorable outcome in patients with
oro-and hypopharyngeal carcinoma (Pretscher et al., 2009). The
emerging evidence for a significant role of the B-cell signature
as a biomarker of prognosis and possibly of metastasis in sev-
eral human malignancies deserves careful attention particularly in
view of novel insights into functional heterogeneity of this lym-
phocyte subset, which appears to play a pivotal role in regulating
T-cell responses (Biragyn and Lee-Chang, 2012).
SUPPRESSOR CELLS IN THE TUMOR MICROENVIRONMENT
Accumulations of regulatory T cells (Treg) and myeloid-derived
suppressor cells (MDSC) in human tumors and their increased
frequency in the circulation of cancer patients have been widely
reported (Marigo et al., 2008; Whiteside, 2012). Many reports, but
not all, link these accumulations of CD4+FOXP3+CD25high Treg
to poor prognosis presumably due to suppression of anti-tumor
responses by the accumulating Treg (Whiteside, 2012). In ovar-
ian carcinoma, melanoma, breast cancer, and glioblastoma, the
frequency of Treg among TIL correlated with tumor grade and
reduced patient survival (Lanca and Silva-Santos, 2012). How-
ever, in other cancers, notably CRC, the presence and density of
FOXP3+ Treg have been reported to predict favorable outcome
and a better locoregional control of the tumor (Badoual et al.,
2006; Salama et al., 2009). These discrepant results are based on
the prevalent use of FOXP3 transcription factor expression as a
marker of Treg. However, a recent comprehensive review of the
prognostic significance of FOXP3+ T cells in 16 non-lymphoid
cancers suggested that FOXP3 by itself is not a reliable marker
of human Treg and that the tumor site, i.e., the tumor microen-
vironment, has a major impact on biologic effects of FOXP3+
Treg (deLeeuw et al., 2012; Whiteside, 2012). Because Treg are het-
erogeneous, consisting on many subsets of functionally distinct
cells, and because no universal distinguishing marker for human
Treg is currently available, their use as a biomarker of progno-
sis is limited and has to be taken with caution. Furthermore,
current attempts to therapeutically deplete Treg might enhance
tumor immunity in some patients but be detrimental in others
(deLeeuw et al., 2012; Whiteside, 2012). Overall, the prognos-
tic value of FOXP3+ Treg in cancer is questionable, although it
is possible that the introduction of more specific assays for Treg
might provide a more discriminating approach for evaluating their
prognostic value.
A similar situation exists with respect to MDSC. Their accu-
mulations in the tumor and blood of cancer patients have also
been correlated to poor clinical outcome (Marigo et al., 2008; Ray-
chaudhuri et al., 2011). The problem that confounds their use as
biomarkers of outcome is twofold. First, their tremendous pheno-
typic and functional heterogeneity of the myeloid compartment
creates a situation where everyone evaluates a different subset mak-
ing it impossible to compare results. For example, a subset of
HLA-DRnegLinneg MDSC present in the human peripheral blood
contains cells with monocytic and granulocytic features, which
can be subdivided into at least four distinct subsets (CD33+,
CD11b+, CD15+, and CD14+) and which differ with respect to
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mechanisms used for suppression (Greten et al., 2011). A recently
proposed immunophenotyping schema for MDSC, which utilizes
multi-parameter flow cytometry, provides a unifying approach to
future evaluations of the role these cells play in disease (Dumitru
et al., 2012). This, however, does not eliminate the second prob-
lem of the sensitivity of CD15+ and CD33+ MDSC subsets to
cryopreservation (Kotsakis et al., 2012). Only the frequency of
CD14+ and CD11b+ subsets was not significantly decreased after
PBMC cryopreservation, although their ability to produce ROS
after ex vivo stimulation was lost (Kotsakis et al., 2012). These
findings led to a conclusion that studies of human MDSC should
be performed in fresh blood samples (Kotsakis et al., 2012). This
requirement not only complicates monitoring of MDSC in clin-
ical trials but significantly lessens their usefulness as potential
prognostic biomarkers.
While both Treg and MDSC clearly play an important role
in cancer progression and perhaps responses to immunotherapy,
their usefulness as biomarkers of outcome or response to ther-
apy has to await further development of monitoring assays that
better reflect their biologic significance in cancer. In addition,
a recent report on regulatory B cells (Biragyn and Lee-Chang,
2012) reminds us that this small subset of suppressor cells may
have profound effects on the development of T-cell responses,
further complicating the interpretation of anti-tumor immune
suppression in disease.
THE NEUTROPHIL-TO-LYMPHOCYTE RATIO
Chronic inflammation is closely associated with the develop-
ment of certain human cancers. For example, inflammatory bowel
disease predisposes to the development of CRC, and human
papilloma virus (HPV) infection is associated with oropharyn-
geal squamous cell carcinoma. Evidence has accumulated that the
total white blood count and especially the elevated neutrophil-to-
lymphocyte ratio (NLR) measured prior to oncological therapies
predicts adverse clinical outcome in patients with lung, breast,
renal, ovarian, and HNC (Perisanidis et al., 2013). Further, the
high NLR is a significant but not yet validated marker of poor
response to chemotherapy (Perisanidis et al., 2013). These obser-
vations fit well with previously reported low lymphocyte counts
in patients with cancer (Kuss et al., 2005). As discussed above,
we have reported spontaneous apoptosis of circulating CD8+
antigen-responding effector T cells, leading to rapid lymphocyte
turnover and depressed absolute numbers of T cell subsets in can-
cer patients tested prior to oncologic therapies (Whiteside, 2005).
Together, these data identifying the high pretreatment NLR as a
significant independent predictor of poor cancer-specific survival
provide a strong rationale for considering a rapid validation of this
promising biomarker.
CYTOKINE EXPRESSION AND LEVELS
Cytokine gene or protein profiling, whether by multiplex
immunoassays, microarrays, or proteomics technologies, is espe-
cially well suited to evaluations of the tumor microenviron-
ment. Given the key role it has in shaping local and systemic
immune responses, events, and interactions between cells found
in this milieu are of prime interest. Cytokines and chemokines
mediate these interactions. Therefore, the potential for capturing
polarization in the cytokine repertoire or differences in patterns
of their production by immune or tumor cells and of relating
them to a specific clinical response has a tremendous appeal.
Systemic and local therapies with cytokines are becoming increas-
ingly common, and there is a need for monitoring cytokine levels
in relation to clinical endpoints. Such monitoring has greatly
expanded our knowledge of the cytokine biology and has pro-
vided clinically useful information about cytokine involvement
in human disease. In cancer, considered to be a Th2-dominant
disease with excess of IL-4, IL-5, IL-10, and TGF-β production,
a therapeutically driven shift back toward the Th1 profile is of
interest, as it might correlate with immune and perhaps clini-
cal recovery (Lucey et al., 1996). Indeed, plasma cytokines have
been used as prognostic biomarkers in cancer (Hanash et al.,
2008), with individual cytokines emerging as especially promis-
ing markers of survival. For example, elevated circulating levels
of IL-6 have been associated with decreased survival in patients
with cancer (Schafer and Brugge, 2007). The production of pro-
inflammatory cytokines, IL-1β, IL-6, and TNFα, all of which
facilitate tumor growth, in the tumor microenvironment might
be due to STAT3 hyperactivation in both the tumor and immune
cells (Yu et al., 2007). While cytokines and chemokines can be
measured in the patients’ body fluids circulation by many differ-
ent methods, multiplex bead immunoassays designed to work in
conjunction with a Luminex-type instrument have all but replaced
traditional ELISA. These assays allow for a simultaneous measure-
ment of pro-inflammatory cytokines, Th1 vs. Th2-type cytokines,
growth-promoting as opposed to suppressive cytokines, etc., in a
small (0.5 mL) sample of a body fluid. The result is a quantita-
tive profile of as many as 20–30 cytokines, and changes in this
profile can be sequentially followed in the course of a clinical
trial. Suppressed levels of Th1 cytokines (IFN-γ, IL-12, TNF-α)
and elevated levels of Th2 cytokines (IL-4, IL-10, TGF-β) have
been seen in patients with cancer, while the opposite pattern is
seen in healthy individuals (Guida et al., 2007). A recent meta-
analysis of cytokine profiles and their clinical significance has been
published (Lippitz, 2013), and it summarizes the current insights
into their diagnostic and prognostic value. To date, the use of
cytokine/chemokine profiles as biomarkers of prognosis of cancer
has been largely limited to retrospective analyses performed with
banked serum specimens. As levels of these mediators in body
fluids might be unstable upon extended cryopreservation (Butter-
field et al., 2011b; Potter et al., 2012), it should be remembered
that retrospective measurements of cytokines are highly prone
to errors resulting from handling of samples, as also previously
emphasized (Whiteside, 2002). To avoid pitfalls due to long-term
storage and sample freezing/thawing, cytokine analyses should be
performed with fresh, prospectively collected specimens tested in
rigorously controlled assays (Butterfield et al., 2011b). However,
even prospective monitoring for cytokines may be biased by the
fact that current antibody-based assays measure soluble mediators,
while those tethered to membranes of microvesicles present in
body fluids remain undetected, as recently reported (Szczepanski
et al., 2011). For this reason, the usefulness of cytokine/chemokine
profiles as surrogate biomarkers of cancer progression remain
limited and further studies linking these profiles with clinical
outcomes are in order.
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TUMOR-DERIVED EXOSOMES
Tumor-derived exosomes have recently come into the limelight as
potential biomarkers in cancer. These membranous nanovesicles
(50–100 nM in diameter) carry a large variety of cellular compo-
nents, including proteins, RNA, microRNA, and DNA (Iero et al.,
2008; Whiteside, 2013). TEX molecular content closely reflects
that of tumor cells from which they originate, and thus TEX can
serve as a sort of “liquid biopsy” in place of a conventional tissue
biopsy. For this reason, molecular profiles of TEX are of great cur-
rent interest. In our early studies of TEX, to establish a correlation
of TEX with progression in HNSCC, we linked TEX functional
activity (i.e., their ability to induce apoptosis of activated CD8+ T
cells) with well-known markers of tumor progression, such as dis-
ease activity, lymph node involvement, and tumor stage (Kim et al.,
2005b; Bergmann et al., 2009). The data showed that TEX present
in plasma of HNSCC patients induced high levels of pan-caspase
activity in CD8+ Jurkat cells or in activated primary CD8+ T cells
(Kim et al., 2005b; Bergmann et al., 2009). This TEX-mediated
effect was further enhanced when TEX were isolated from in
patients with late-stage compared to early-stage tumors. More
recent studies suggest that the total protein levels of TEX iso-
lated from plasma and their molecular content reflect the tumor
presence, its progression or regression after therapy and possibly
its recurrence (Somasundaram and Herlyn, 2012). Exosome frac-
tions obtained from the plasma of melanoma patients with stage
IV disease had the highest protein concentrations relative to exo-
somes of patients with less advanced disease. Also, stage IV patients
with protein-poor exosomal fractions had a significant survival
advantage over those with protein-rich exosomes (Peinado et al.,
2012). Our own preliminary data similarly show that the pro-
tein content of isolated TEX (in µg/mL plasma) in patients with
advanced melanoma are higher than those in patients with early
disease. In aggregate, these data suggest that the protein content of
isolated TEX alone may be a biomarker of prognosis in cancer. In
murine melanoma, TEX contributed to metastatic invasion by car-
rying messenger proteins that direct bone-marrow-derived cells
toward a pro-metastatic phenotype (Peinado et al., 2012; Soma-
sundaram and Herlyn, 2012). We recently showed that exosomes
isolated from sera of AML patients at diagnosis inhibited func-
tions of NK cells via membrane-tethered TGF-β and observed by
using western blots that levels of this exosome-bound cytokine
decreased during remission (Szczepanski et al., 2011). TEX carry
and present membrane-bound enzymes, receptors, and cytokines
to target cells, serving as message carriers and delivering signals
to immune and tissue cells (Iero et al., 2008; Whiteside, 2013).
Because membrane-bound proteins often have greater biologi-
cal effects than their soluble counterparts, analysis of TEX might
be of greater prognostic value than are measures of serum pro-
teins. Currently, methods for capture of TEX to separate them
from exosomes secreted by normal cells in the plasma of cancer
patients are under development. With this technical improvement,
the potential value of TEX as biomarkers of the tumor fate during
and after therapy can be confirmed in future prospective studies.
CONCLUSION
Despite considerable recent progress in the type and quality
of immunologic monitoring applicable to clinical trials, linking
results of correlative immunologic studies with clinical endpoints
has been difficult and frustrating. In part, this might reflect the bio-
logic variability inherent to the immune system and a demanding
nature of serial immunologic studies, which require specialized
and highly proficient laboratory support. It is also likely that the
characteristics of tumor cells influence the potential of immune
responses to serve as useful biomarkers of prognosis. Nevertheless,
a number of promising immunologic biomarkers have emerged
recently, perhaps as a result of improved high-through tech-
nologies incorporating proteomic and genomic platforms and of
greater attention to changes in personalized immune profiles of
cancer patients treated with conventional, biologic, or combina-
tion therapies. Most of these changes, whether reflecting cancer
presence, progression, or response to therapy, have a potential to
serve as intermediate biomarkers of outcome. However, only few,
including T-cell and B-cell immune signatures or the NLR, have
been validated in independent clinical studies encompassing large
cohorts of patients with different tumor types (Schmidt et al.,
2008, 2012; Perisanidis et al., 2013). Most of the other immune
biomarkers showing promise in preliminary evaluations have yet
to be validated, and much work remains to confirm their reliable
association with clinical endpoints. Considering the data reviewed
above, it would be reasonable to assume that good prognosis asso-
ciates with CD8+ T cell and CD20+ B cell infiltrates into the
tumor, while accumulations of Treg or MDSC are linked with
bad outcome. Further, given the functional differences between
immune cell subsets, a distinct outcome could be expected from
Th1 vs. Th2 or vs. Th17+CD4+ cell profiles or from tumors infil-
trated by M1 vs. M2 cells. Not only the phenotype, the frequency
and functions of these various cell subsets might be important
for prognosis but also their localization at the tumor site and
their compartmentalization between the tumor and the periphery.
Thus, substituting IHC by sophisticated but much more reliable
image analysis coupled with precise clinicopathologic analysis and
clinical follow-up in well-defined, relatively uniform cohorts of
patients offers the best option for confirming immune endpoints
as biomarkers of outcome. This approach has been most success-
fully used by the French investigators in CRC, and their experience
in hierarchical clustering of signature T-cell transcripts (Galon
et al., 2006; Camus et al., 2009; Pages et al., 2010; Fridman et al.,
2011, 2012) paves the way for integrating immune cell signa-
tures with prognosis in other tumor types. Much work remains to
confirm the reliable association of immune biomarkers with clin-
ical endpoints and to validate each of these potentially promising
biomarker in a series of prospective clinical trials.
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